Table 3 Risk factors for nephrotoxicity
From: Vancomycin dosing design method considering risk factors for nephrotoxicity
Risk factor | Univariate logistic regression analyses | Multivariate logistic regression analyses | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Odds Ratio | 95%CI | p-value | Odds Ratio | 95%CI | p-value | |||||
AST (IU/L) | 1.001 | 0.993 | - | 1.008 | 0.703 | - | - | - | - | - |
ALT (IU/L) | 1.000 | 0.993 | - | 1.005 | 0.995 | - | - | - | - | - |
High dose of VCM (4 g/day) | 5.556 | 0.895 | - | 43.17 | 0.065 | 6.971 | 0.519 | - | 93.57 | 0.143 |
AUCss (mg·h/L) | 1.005 | 1.003 | - | 1.008 | < 0.0001 | 1.006 | 1.004 | - | 1.009 | < 0.0001 |
Dosing for more than 14 days | 1.875 | 0.974 | - | 3.625 | 0.060 | 2.137 | 0.987 | - | 4.627 | 0.054 |
Chronic hepatic disease | 3.434 | 1.143 | - | 10.13 | 0.029 | 4.273 | 1.285 | - | 14.21 | 0.018 |
TAZ/PIPC | 2.555 | 0.998 | - | 6.282 | 0.050 | 4.627 | 1.562 | - | 13.70 | 0.006 |
AGs | 11.18 | 1.394 | - | 229.0 | 0.023 | 10.12 | 0.752 | - | 136.4 | 0.081 |
Diuretic | 2.425 | 1.259 | - | 4.742 | 0.008 | 2.189 | 1.012 | - | 4.736 | 0.047 |
NSAIDs | 2.215 | 0.950 | - | 4.976 | 0.065 | - | - | - | - | - |